Reviva Pharmaceuticals Holdings, Inc., a clinical stage pharmaceutical company, develops therapies to address unmet medical needs in the areas of central nervous system, cardiovascular, metabolic, and inflammatory diseases. Its lead product candidate is RP5063 for the treatment of schizophrenia, bipolar disorder, and major depressive disorder, as well as for treating pulmonary arterial hypertension and idiopathic pulmonary fibrosis. The company is based in Cupertino, California.